Recombinant human complement factor H - Eleva
Alternative Names: Compleva FH; CPV-104Latest Information Update: 11 Feb 2025
At a glance
- Originator Eleva
- Class Eye disorder therapies; Recombinant proteins; Urologics
- Mechanism of Action Complement factor H replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Dry age-related macular degeneration; Membranoproliferative glomerulonephritis
Most Recent Events
- 04 Feb 2025 Preclinical trials in Dry age-related macular degeneration in Germany (Intravitreous)
- 04 Feb 2025 Eleva plans a phase I clinical trial in Membranoproliferative glomerulonephritis in H1 2025 (Parenteral)
- 03 Jul 2024 Recombinant human complement factor H - Eleva receives Orphan Drug status for Membranoproliferative glomerulonephritis in European Union